Company Registration No. 11463193 (England and Wales)
Life Science Futures Limited
Unaudited financial statements
for the year ended 31 December 2025
Pages for filing with the registrar
Life Science Futures Limited
Contents
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 6
Life Science Futures Limited
Statement of financial position
As at 31 December 2025
1
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
3
442,802
407,999
Current assets
Debtors
4
399
399
Cash at bank and in hand
114,830
74,285
115,229
74,684
Creditors: amounts falling due within one year
5
(97,718)
(98,558)
Net current assets/(liabilities)
17,511
(23,874)
Net assets
460,313
384,125
Capital and reserves
Called up share capital
6
62,506
62,506
Profit and loss reserves
397,807
321,619
Total equity
460,313
384,125

The director of the company has elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 10 September 2026.
Mr K  McCullagh
Director
Company Registration No. 11463193
Life Science Futures Limited
Statement of changes in equity
For the year ended 31 December 2025
2
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2024
62,506
252,332
314,838
Year ended 31 December 2024:
Profit and total comprehensive income
-
69,287
69,287
Balance at 31 December 2024
62,506
321,619
384,125
Year ended 31 December 2025:
Profit and total comprehensive income
-
76,188
76,188
Balance at 31 December 2025
62,506
397,807
460,313
Life Science Futures Limited
Notes to the financial statements
For the year ended 31 December 2025
3
1
Accounting policies
Company information

Life Science Futures Limited is a private company limited by shares incorporated in England and Wales. The registered office is 240 Blackfriars Road, London, SE1 8NW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Fixed asset investments

Financial fixed assets, including investments in funds are initially measured at the transaction price. Due to the absence of an active market and an inability to reliably measure the fair value these assets are subsequently carried and measured at cost less impairment.

1.3
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Life Science Futures Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
1
Accounting policies (continued)
4
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.6
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
3
Fixed asset investments
2025
2024
£
£
Other investments other than loans
442,802
407,999
Life Science Futures Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
3
Fixed asset investments (continued)
5
Movements in fixed asset investments
Investments
£
Cost or valuation
At 1 January 2025
407,999
Additions
34,803
At 31 December 2025
442,802
Carrying amount
At 31 December 2025
442,802
At 31 December 2024
407,999
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
399
399
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
-
0
840
Other creditors
97,718
97,718
97,718
98,558
6
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A shares of £1 each
1
1
1
1
Ordinary shares of £1 each
62,505
62,505
62,505
62,505
62,506
62,506
62,506
62,506

The company has two classes of shares. Ordinary shares which have equal voting and dividend rights and distribution rights on a winding up of the company. A shares entitle the holder to appoint and remove directors at any time as well as the right to veto specified actions of the company.

Life Science Futures Limited
Notes to the financial statements (continued)
For the year ended 31 December 2025
6
7
Financial commitments, guarantees and contingent liabilities

During the year, the Company continued to hold its interests in FFV 3 Feeder COOPERATIEVE U.A, FFV 4 Feeder COOPERATIEF U.A and FFV 5 Feeder COOPERATIEF U.A funds. The company has agreed to make capital contributions when requested by the funds to a maximum of €250,000. As such the remaining contribution which could be called is £26,140 (2024: £24,859) for FFV 3, £nil (2024: £729) for FFV 4 and £60,595 (2024: £79,657) for FFV 5 each respective fund translated at the spot rate as at 31 December 2024. This commitment has not been recognised in these financial statements.

8
Directors' transactions

During the year Keith McCullagh, who is a director of the company, introduced capital to the company totalling £nil (2024: £nil). At the year end the amount due to the director was £97,718 (2024: £97,718), which is included within other creditors.

2025-12-312025-01-01falsefalsefalse14 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityKeith McCullagh114631932025-01-012025-12-31114631932025-12-31114631932024-12-3111463193core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3111463193core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3111463193core:CurrentFinancialInstruments2025-12-3111463193core:CurrentFinancialInstruments2024-12-3111463193core:ShareCapital2025-12-3111463193core:ShareCapital2024-12-3111463193core:RetainedEarningsAccumulatedLosses2025-12-3111463193core:RetainedEarningsAccumulatedLosses2024-12-3111463193core:ShareCapital2023-12-3111463193core:RetainedEarningsAccumulatedLosses2023-12-3111463193core:ShareCapitalOrdinaryShareClass12025-12-3111463193core:ShareCapitalOrdinaryShareClass12024-12-3111463193core:ShareCapitalOrdinaryShareClass22025-12-3111463193core:ShareCapitalOrdinaryShareClass22024-12-3111463193core:ShareCapitalOrdinaryShares2025-12-3111463193core:ShareCapitalOrdinaryShares2024-12-3111463193bus:Director12025-01-012025-12-3111463193core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31114631932024-01-012024-12-3111463193core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3111463193bus:OrdinaryShareClass12025-01-012025-12-3111463193bus:OrdinaryShareClass22025-01-012025-12-3111463193bus:OrdinaryShareClass12025-12-3111463193bus:OrdinaryShareClass12024-12-3111463193bus:OrdinaryShareClass22025-12-3111463193bus:OrdinaryShareClass22024-12-3111463193bus:AllOrdinaryShares2025-12-3111463193bus:AllOrdinaryShares2024-12-3111463193bus:PrivateLimitedCompanyLtd2025-01-012025-12-3111463193bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3111463193bus:FRS1022025-01-012025-12-3111463193bus:AuditExemptWithAccountantsReport2025-01-012025-12-3111463193bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP